Published in Drug Week, January 27th, 2006
The sBLA submission is based on results of a randomized, controlled, multicenter phase III trial (E3200) of 829 patients with advanced or metastatic colorectal cancer (CRC) whose disease progressed following previous treatment...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Drug Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.